Anlon Healthcare Subscription Status:
At the end of the first day of the subscription, the IPO of Anlon Healthcare was subscribed to 1.69 times, according to data from the stock exchanges. Retail individual investors (Riis) showed a strong interest and subscribed 8.98 times the 13.30 Lakh shares that were offered. Non-institutional investors (NIIs) have subscribed to 71% of the 19.95 LAKH shares that are available and qualified institutional buyers (QIBS) bids for 91% of the shares of 99.75 LAKH that are assigned to them.
Anlon Healthcare GMP today
Anlon Healthcare IPO is traded with a premium of 4.4% on the gray market, priced above the higher tire issue of RS 91, indicating a light premium prior to the offer.
GMP Note: Gray Market Premium (GMP) reflects the unofficial premium investors who are willing to pay before the official list.
Anlon Healthcare IPO -Details
The RS 121 Crore IPO from Anlon Healthcare was open for subscription on 26 August and will close on August 29. The company provides a new range of 1.33 crore shares shares, priced between RS 86 and RS 91 per share.
The party size is set at 164 shares, making the minimum retail investment approximately RS 14,924. The IPO is managed by interactive financial services, with KFIN technologies that serve as a registrar. The shares are expected to be mentioned on the NSE SME platform on 3 September.
Company background
Anlon Healthcare, with headquarters in Rajkot, Gujarat, is a chemical production company that specializes in pharmaceutical intermediates with high purity and active pharmaceutical ingredients (APIs). The products are used as raw materials in the production of tablets, capsules, ointments, nutraceuticals, products for personal care and veterinary APIs.
The company is one of the few domestic manufacturers of Loxoprofen sodium dihydrate, a commonly used treatment for arthritis, back pain and post-surgical inflammation. It has also submitted several drugmaster files (DMFs) in regions, including the EU, Russia, Japan, South Korea, and is currently continuing files at the US FDA.
The product portfolio of Anlon Healthcare comprises more than 65 commercialized products, with 28 in the pilot phase and 49 laboratory tests undergo.
For FY25, the company reported the turnover of RS 120 Crore, a significant increase in RS 66 Crore in FY24, and the net profit rose to RS 20.5 Crore of RS 9.7 Crore in the previous year.
Use of yields
Funds collected via the IPO will be used to expand production facilities, repay certain loans and support general business purposes.
Do you have to subscribe?
Brokerage company Anand Rathi has given the IPO a “Subscribe – long -term” rating, with the emphasis on the robust and diversified product portfolio of Anlon, scalable business model and approvals in several regions.
However, the memorandum warns that the IPO is “fully priced” with a 19x p/e ratio based on FY25 income and an EV/EBITDA of 16.7x. It suggests the problem mainly for investors with a long -term investment perspective.
The most important risks are emphasized, including stringent regulatory testing, potential plant exclusion and vulnerability for product quality audits that can lead to cancellations or delays.
(Disclaimer: recommendations, suggestions, views and opinions of the experts are their own. These do not represent the views of economic times)
#Anlon #Healthcare #IPO #subscribed #times #day #GMP #bid